A proposed score for assessing progression in PT1 high-grade urothelial carcinoma of the bladder

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 3, 2013, Pages 218-227

  Raspollini, Maria Rosaria ^a   Minervini, Andrea ^a   Lapini, Alberto ^a   Lanzi, Federico ^a   Rotellini, Matteo ^a   Baroni, Gianna ^a   Carini, Marco ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

immunohistochemistry; progression; pT1 high grade urothelial carcinoma; recurrence; score

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; GALECTIN 3; HERMES ANTIGEN; HYALURONIDASE; PROTEIN P16; SURVIVIN; SYNDECAN 1; UVOMORULIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PAPILLARY CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84877002827     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31825f3264     Document Type: Article

References (31)

1. Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer. 1995;31A:1840-1846.
2. Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992;19: 499-508.
3. Sylvester RJ, Van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49: 466-477.
4. Yin W, Chen N, Zhang Y, et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol. 2006;19:1487-1497.
5. Ather MH, Zaidi M. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European Organization of research and treatment of cancer risk tables. Urol J. 2009;6: 189-193.
6. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUOTO scoring model. J Urol. 2009;182:2195-2203.
7. Depowski PL, Rosenthal SI, Brien TP, et al. Topoisomerase II alpha expression in breast cancer: correlation with outcome variable. Mod Pathol. 2000;13:542-547.
8. Costa MJ, Hansen CL, Holden JA, et al. Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol. 2000;19:248-257.
9. Kim E-J, Lee Y-S, Kim Y-J, et al. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology. 2010;75: 1515.e9-1513.e9.
10. Yin M, Bastacky S, Parwani AV, et al. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol. 2007;39:527-535.
11. Buza N, Cohen PJ, Hui P, et al. Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder. Int J Surg Pathol. 2010;18:94-b102.
12. Raspollini MR, Sardi I, Giunti L, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. Hum Pathol. 2011;42:1149- 1158.
13. Ross JS, del Rosario AD, Bui HX, et al. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol. 1996;9:854-860.
14. Lipponen P, Aaltoma S, Kosma V-M, et al. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol. 1998;186:157-164.
15. Vrooman OPJ, Witjes JA. Urinary markers in bladder cancer. Eur Oncol. 2008;50:909-916.
16. Weiss C, Von Romer F, Capalbo G, et al. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys. 2009;74:1455-1460.
17. Skrincosky D, Hallen HJ, Bernacki RJ. Galaptin-mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptin binding proteins. Cancer Res. 1993;53:2667-2675.
18. Lotan R, Ito H, Yasui W, et al. Expression of a 31-kDa lactosidebinding lectin in normal and human gastric mucosa and in primary and metastatic gastric carcinoma. Int J Cancer. 1994;56:474-480.
19. Van Den Brule FA, Berchuck A, Bast RC, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol. 1996;27:1185-1191.
20. Castronovo V, Van Den Brule FA, Jackers P, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996;179:43-48.
21. Cindolo L, Benvenuto G, Salvatore P, et al. Galectin-1 and galectin- 3 expression in human bladder transitional cell carcinomas. Int J Cancer. 1999;84:39-43.
22. Kramer MW, Kuczyk MA, Hennenlotter J, et al. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. Oncol Rep. 2008;20:1403-1408.
23. Canesin G, Gonzalez-Peramato P, Palou J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol. 2010;31:277-285.
24. O'Connell FP, Pinkus JL, Pinkus GS. CD138 (Syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121: 254-263.
25. Nikolova V, Koo CY, Ibraim SA, et al. Differential roles for membrane-bound and soluble syndecan (CD138) in breast cancer progression. Carcinogenesis. 2009;30:397-407.
26. Shimada K, Nakamura M, Anai S, et al. A novel human AlkB homologue, AALKBH8, contributes to human bladder cancer progression. Cancer Res. 2009;69:3157-3164.
27. Bologna-Molina R, Gonzales-Gonzales R,Mosqueda-Taylor A, et al. Expression of syndecan-1 in papillary carcinoma with extracapsular invasion. Arch Med Res. 2010;41:33-37.
28. Shimada K, Nakamura M, De Velasco MA, et al. Role of syndecan- 1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci. 2010;101:155-160.
29. Lokeshwar VB, Young MJ, Goudarzi G, et al. Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res. 1999;49:4464-4470.
30. Lokeshwar VB, Cerwinka WH, Lokeshwar BL. HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res. 2005;65:2243-2250.
31. Erdemir F, Ozcan F, Kilicaslan I, et al. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol. 2007;39:1031-1037.